Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 12/20 | 0.49 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.49 |
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 0.49 |
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 3/20 | 0.41 |
| ▸ | THRB | P10828 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21189492 | 0.91 | CHRM3 (0.40) | MAPTGPR35GPR55CNR1NPSR1 | |
| SCHEMBL19973909 | 0.90 | IDO1 (0.40) | MAPTGPR35GPR55CNR1NPSR1 | |
| SCHEMBL19973907 | 0.90 | IDO1 (0.40) | MAPTGPR35GPR55CNR1NPSR1 | |
| SCHEMBL21189310 | 0.89 | MAPT (0.40) | MAPTGPR35GPR55CNR1NPSR1 | |
| SCHEMBL21189385 | 0.88 | CHRM3 (0.38) | MAPTGPR35GPR55CNR1NPSR1 | |
| SCHEMBL19973963 | 0.86 | MCHR1 (0.40) | MAPTLMNAMEN1KMT2ATP53 | |
| SCHEMBL21189186 | 0.86 | MAPT (0.44) | MAPTGPR35GPR55CNR1NPSR1 | |
| SCHEMBL21189382 | 0.84 | KMT2A (0.39) | MAPTLMNAMEN1KMT2ATP53 | |
| SCHEMBL19973622 | 0.84 | CHRM1 (0.47) | ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL19973889 | 0.84 | CHRM1 (0.46) | ALDH1A1MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11001564-B2 | Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same | ARBUTUS BIOPHARMA CORPORATION (CA) | 2021-05-11 | — | — | US | disclosed |
| US-20190225593-A1 | SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (CA) | 2019-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190225593-A1 | SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME | CBX8, HAVCR2, HCCS | MAPT 3165/4885GPR35 1322/4885GPR55 1817/4885 |
| US-11001564-B2 | Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same | CBX8, HAVCR2, HCCS | MAPT 3165/4885GPR35 1322/4885GPR55 1817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.